Compare CubeSmart (CUBE) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CubeSmart vs Mesoblast Limited — how do they compare? CubeSmart trades at $40.56 (market cap $9.19B), while Mesoblast Limited trades at $16.95 (market cap $2.09B). The key difference: CubeSmart is far larger — about 4.4× Mesoblast Limited's market cap, and CubeSmart pays a 5.22% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| CUBE | MESO | |
|---|---|---|
Market Cap | $9.19B | $2.09B |
Sector | Real Estate | Technology |
52-Week High | $42.34 | $20.96 |
52-Week Low | $35.36 | $10.96 |
Enterprise Value | $12.69B | $2.10B |
Dividend Yield | 5.22% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CubeSmart
CubeSmart is a real estate investment trust that acquires, owns, and manages self-storage facilities throughout the United States. The company's real estate portfolio is composed of buildings with numerous enclosed storage areas for both residential and commercial customers to rent mainly on a month-by-month basis. Most of CubeSmart's facilities are located in Florida, Texas, California, New York, and Illinois. Cumulatively, these states account for both the majority of the square footage in the company's real estate portfolio and the majority of its revenue. CubeSmart derives nearly all of its revenue from rental income from tenants utilizing its storage facilities.
Read more on CUBE →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
